Training Program in Cancer Biology
Training Program in Cancer Biology
批准号:
10670055
负责人:
Scott D Cramer
金额:
$39.44万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
未结题
起止时间:
2016-07-07 至 2027-07-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
Despite major breakthroughs over the past few years in our basic understanding of the cellular and molecular
changes that lead to cancer, many key steps in carcinogenesis and changes in early cancers that promote
invasion and metastasis, still remain poorly defined. Rigorous training of future young investigators in cancer
biology will be essential in our quest for a deeper understanding of carcinogenesis and for the development of
better methods of early cancer detection, improved diagnosis, and effective new cancer treatments. The
Training Program in Cancer Biology (TPCB) is a multidisciplinary program across all cancer subtypes that
capitalizes on the unique strengths and training opportunities at CU Anschutz, including world renowned
research in functional genomics, experimental therapeutics, steroid receptor signaling, stem cells and organ
specific cancers (in particular lung, breast and blood). Our goal is to provide interdisciplinary training at the
cutting edge of cancer research to best prepare our trainees to compete in a biomedical research environment
increasingly focused on translational applications of basic research. Our training plan consists of laboratory
training, didactic activities, attendance at scientific conferences, professional development and career
mentoring, development of communication skills, and exposure to the clinical perspective. Based on feedback
from trainees and faculty, for this renewal we have added new training components, including mandatory
mentor training and training in rigor and reproducibility. The renewal also includes expanded opportunities for
training in quantitative biology and bioinformatics, and expanded clinical/translational and career development
opportunities. The co-PIs of this training program have been leaders in Cancer Biology training at the
University of Colorado Cancer Center and the Graduate School during the past 10 years. Resources from the
Cancer Center, the Graduate School, and individual departments are committed to support the training
program. The infrastructure of the Cancer Center is particularly important as it provides core resources
available to training faculty that are therefore available to the trainees. The proposed program will include pre-
doctoral training through the graduate training program in Cancer Biology, which is housed in the Graduate
School, and post-doctoral training for PhD and PhD/MD scientists. A total of 38 training faculty were selected
based on their scientific expertise and track record of mentorship. The first cycle of this T32 grant was highly
successful, with all slots competitively filled. For the second cycle of this grant, we propose to support 4
postdoc and 4 predoctoral trainees each year. We will select trainees from external and internal pools based
on their research and academic records and commitment to cancer research. We are committed to providing
comprehensive training at all levels so as to best prepare our trainees for successful careers in biomedical
science inside or outside academia.
期刊论文(16)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1038/s41389-017-0015-5
发表时间:
2018-02-28
期刊:
Oncogenesis
影响因子:
6.2
作者:
[Beadnell TC, Nassar KW, Rose MM, Clark EG, Danysh BP, Hofmann MC, Pozdeyev N, Schweppe RE]
通讯作者:
Schweppe RE
DOI:
10.3390/cancers13133272
发表时间:
2021-06-30
期刊:
Cancers
影响因子:
5.2
作者:
[Jillson LK, Yette GA, Laajala TD, Tilley WD, Costello JC, Cramer SD]
通讯作者:
Cramer SD
DOI:
10.1172/jci161659
发表时间:
2022-07-15
期刊:
JOURNAL OF CLINICAL INVESTIGATION
影响因子:
15.9
作者:
[Evans, Edward J., Jr., DeGregori, James]
通讯作者:
DeGregori, James
DOI:
10.1007/s12672-017-0314-5
发表时间:
2018-04
期刊:
Hormones & cancer
影响因子:
3
作者:
[Christenson JL, Trepel JB, Ali HY, Lee S, Eisner JR, Baskin-Bey ES, Elias AD, Richer JK]
通讯作者:
Richer JK
CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies.
DOI:
10.1182/bloodadvances.2023010162
发表时间:
2023-11-14
期刊:
BLOOD ADVANCES
影响因子:
7.5
作者:
[de Acha, Olivia Perez, Reiman, Lauren, Jayabalan, David S., Walker, Zachary J., Bosma, Grace, Keller, Alana L., Parzych, Sarah E., Abbott, Diana, Idler, Beau M., Ribadeneyra, Drew, Niesvizky, Ruben, Forsberg, Peter A., Mark, Tomer M., Sherbenou, Daniel W.]
通讯作者:
Sherbenou, Daniel W.
共 14 条
Androgen Signaling in CaP with loss of MAP3K7 and CHD1
-
批准号:10657393
-
项目类别:
-
资助金额:$38.41万
-
财政年份:2021
-
负责人:Scott D Cramer
-
依托单位:
Androgen Signaling in CaP with loss of MAP3K7 and CHD1
-
批准号:10276486
-
项目类别:
-
资助金额:$39.19万
-
财政年份:2021
-
负责人:Scott D Cramer
-
依托单位:
Androgen Signaling in CaP with loss of MAP3K7 and CHD1
-
批准号:10439892
-
项目类别:
-
资助金额:$38.41万
-
财政年份:2021
-
负责人:Scott D Cramer
-
依托单位:
Training Program in Cancer Biology
-
批准号:10332080
-
项目类别:
-
资助金额:$25.18万
-
财政年份:2016
-
负责人:Scott D Cramer
-
依托单位:
Autophagy regulation of prostate tumor development
-
批准号:9096644
-
项目类别:
-
资助金额:$20.29万
-
财政年份:2016
-
负责人:Scott D Cramer
-
依托单位:
Training Program in Cancer Biology
-
批准号:9404559
-
项目类别:
-
资助金额:$0.54万
-
财政年份:2016
-
负责人:Scott D Cramer
-
依托单位:
Training Program in Cancer Biology
-
批准号:9312767
-
项目类别:
-
资助金额:$37.6万
-
财政年份:2016
-
负责人:Scott D Cramer
-
依托单位:
CHD1 and MAP3K7 coordinate deletion in aggressive ERG translocation negative prostate cancer
-
批准号:9265055
-
项目类别:
-
资助金额:$34.19万
-
财政年份:2015
-
负责人:Scott D Cramer
-
依托单位:
CHD1 and TAK1 Synthetic Lethality in Prostate Cancer
-
批准号:8873686
-
项目类别:
-
资助金额:$16.9万
-
财政年份:2015
-
负责人:Scott D Cramer
-
依托单位:
CHD1 and MAP3K7 coordinate deletion in aggressive ERG translocation negative prostate cancer
-
批准号:9090060
-
项目类别:
-
资助金额:$38.87万
-
财政年份:2015
-
负责人:Scott D Cramer
-
依托单位:
CHD1 and TAK1 Synthetic Lethality in Prostate Cancer
-
批准号:9047256
-
项目类别:
-
资助金额:$20.29万
-
财政年份:2015
-
负责人:Scott D Cramer
-
依托单位:
Isolation of Tumor Initiating Cells (TICs) using Contactless Dielectrophoresis
-
批准号:8547799
-
项目类别:
-
资助金额:$18.73万
-
财政年份:2012
-
负责人:Scott D Cramer
-
依托单位:
Isolation of Tumor Initiating Cells (TICs) using Contactless Dielectrophoresis
-
批准号:8431874
-
项目类别:
-
资助金额:$18.03万
-
财政年份:2012
-
负责人:Scott D Cramer
-
依托单位:
The prostate stem cell is a target of vitamin D chemoprevention
-
批准号:8676711
-
项目类别:
-
资助金额:$29.37万
-
财政年份:2010
-
负责人:Scott D Cramer
-
依托单位:
The prostate stem cell is a target of vitamin D chemoprevention
-
批准号:8326107
-
项目类别:
-
资助金额:$30.28万
-
财政年份:2010
-
负责人:Scott D Cramer
-
依托单位:
The prostate stem cell is a target of vitamin D chemoprevention
-
批准号:8469833
-
项目类别:
-
资助金额:$28.46万
-
财政年份:2010
-
负责人:Scott D Cramer
-
依托单位:
The prostate stem cell is a target of vitamin D chemoprevention
-
批准号:8105199
-
项目类别:
-
资助金额:$30.28万
-
财政年份:2010
-
负责人:Scott D Cramer
-
依托单位:
Tak1, a novel prostate cancer tumor suppressor
-
批准号:8053797
-
项目类别:
-
资助金额:$9.31万
-
财政年份:2009
-
负责人:Scott D Cramer
-
依托单位:
Tak1, a novel prostate cancer tumor suppressor
-
批准号:7828004
-
项目类别:
-
资助金额:$30.71万
-
财政年份:2009
-
负责人:Scott D Cramer
-
依托单位:
Tak1, a novel prostate cancer tumor suppressor
-
批准号:8316493
-
项目类别:
-
资助金额:$21.24万
-
财政年份:2009
-
负责人:Scott D Cramer
-
依托单位:
海外基金